Clinical Trial Detail

NCT ID NCT02734004
Title A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors AstraZeneca
Indications

stomach cancer

breast cancer

ovarian cancer

lung small cell carcinoma

Therapies

Durvalumab + Olaparib

Bevacizumab + Durvalumab + Olaparib

Age Groups: adult senior

Additional content available in CKB BOOST